Evidence-Based Therapeutics Group, Clinical Pharmacology, Universidad de La Sabana, 140013 Chía, Colombia.
Riesgo de Fractura S.A.-CAYRE, 110221 Bogotá, Colombia.
Sensors (Basel). 2018 Feb 26;18(3):691. doi: 10.3390/s18030691.
This study describes the development of an immunosensory label-free quantification methodology based on surface plasmon resonance (SPR) and its applicability in measuring/evaluating therapeutic drug monitoring (TDM) of anti-TNF-α monoclonal antibody (adalimumab) in rheumatoid arthritis (RA) patients. The experimental parameters evaluated in this study were immobilising ligands by pre-concentration assays, sensor surface regeneration, ascertaining the method's sensitivity and correlating the results from quantifying plasma samples by ELISA immunoassay. The results showed that TNF-α quantification values (in RU) were significantly different when comparing patients (50-250 RU) to controls (10-20 RU). Likewise, there was 0.97 correlation for patients and 0.91 for healthy volunteers using SPR and ELISA comparison methodologies. SPR immunosensory detection provided a precise, sensitive strategy, along with real-time determination, for quantifying adalimumab, having great potential for clinical routine regarding TDM.
本研究描述了一种基于表面等离子体共振（SPR）的免疫传感无标记定量方法的开发及其在测量/评估类风湿关节炎（RA）患者抗 TNF-α 单克隆抗体（阿达木单抗）治疗药物监测（TDM）中的应用。本研究中评估的实验参数包括通过预浓缩测定法固定配体、传感器表面再生、确定方法的灵敏度以及通过 ELISA 免疫分析法定量血浆样品的结果进行相关性。结果表明，比较患者（50-250 RU）和对照组（10-20 RU）时，TNF-α 定量值（以 RU 表示）有显著差异。同样，使用 SPR 和 ELISA 比较方法，患者的相关性为 0.97，健康志愿者为 0.91。SPR 免疫传感检测为定量阿达木单抗提供了一种精确、灵敏的策略，同时具有实时测定的特点，在 TDM 的临床常规方面具有很大的潜力。
